Polycaprolactone Antimony Nanoparticles as Drug Delivery System for Leishmaniasis.

Background: Leishmaniasis is a neglected disease endemic in tropical and subtropical areas, with an incidence about 1.6 million cases/year. The first-line treatment of this disease is pentavalent antimony, and the second-line are pentamidine and amphotericin B.